NCT02221778

SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Partial Response to Transarterial Chemoembolization

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT). The focus of the study will be to evaluate safety and efficacy in our population of patients.

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
RADIATION	SBRT	SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below: Prescription dose(Gy) / (MLD) (Gy) 50 / 13 45 / 15 40 / 15 35 / 15.5 30 / 16 27.5 / 17 If the dose constraints cannot be met, prescription will be according to the level immediately bellow. Treatment will be delivered in 5 fractions in consecutive working days

Timeline

• Start date: 2014-08-01
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2014-08-20
• Last updated: 2024-12-06

Locations

1 site across 1 country: Brazil